Invitae (NYSE: NVTA) has grown revenue over time, but the genetic testing specialist has failed to turn that into profit. Instead, the company burned through more and more cash, prompting it to launch ...

Invitae announces debt transaction to refinance 2024 notes. Q4 results decent as ongoing restructuring continues. 2023 guidance could have been better. For the quarter, revenue came in at $122.45 ...

Invitae’s (NVTA) significant revenue growth in its most recently reported quarter and its success in bringing customized health monitoring into the mainstream have heightened investor optimism around ...

Invitae's business has been growing rapidly and there's still more growth on the horizon. The beaten-up stock is a risky buy given its significant losses and persistent cash burn. There's significant ...

Invitae, a genetic testing services provider, reported Q1 2023 revenue of $117.4 million, down from Q1 2022's $123.7 million due to exited businesses and geographies. However, after accounting for ...

Bull case: Invitae has launched a plan to reach positive cash flow as soon as possible. Any progress could drive share gains. Bear case: Invitae comes with too much risk in an uncertain market. Could ...

Shares of molecular diagnostics company Invitae (NYSE: NVTA) climbed 10.7% on Tuesday. At this point, investors may be more willing to take a flyer on Invitae, especially since Cathie Wood, the CEO ...

Shares of the genetic testing company have more than doubled in less than a week. It likely isn’t durable. It was also truly bizarre. Invitae announced a strategic pivot and provided financial ...

The shares of genetic testing concern InVitae Corp (NYSE:NVTA) are fresh off an all-time high of $28.38, last seen 1.6% higher at $27.60, thanks to a boost from Citron Research. The firm said it will ...

Invitae (NYSE: NVTA) shares have plummeted more than 80% this year. The genetic testing company has grown revenue over the years, but it hasn't been able to turn that revenue into profit. Instead, ...